Daratumumab, a human IgG1 antibody that targets CD38 and has a direct antitumor and immunomodulatory activity, attaches to the CD38 protein found on the surface of myeloma cells, thereby enabling the immune system to target and kill it. This evidence concerns the gene CD38 and plasma cell myeloma.